Kidney Week

Abstract: INFO14

The Hepatorenal Fibrocystic Disease Core Center

Session Information

• Informational Posters
  October 25, 2018 | Location: Exhibit Hall, San Diego Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category:

• No subcategory defined

Authors

• Yoder, Bradley K., University of Alabama at Birmingham, Birmingham, Alabama, United States

Bradley K. Yoder,

• Guay-Woodford, Lisa M., Children's National Health System, Washington, District of Columbia, United States

Lisa M. Guay-Woodford,

• Bell, P. Darwin, University of Alabama at Birmingham, Birmingham, Alabama, United States

P. Darwin Bell,

• Lipschutz, Joshua H., Medical University of South Carolina, Charleston, South Carolina, United States

Joshua H. Lipschutz,

• Mrug, Michal, University of Alabama at Birmingham, Birmingham, Alabama, United States

Michal Mrug,

Description

The Hepatorenal Fibrocystic Disease Core Center (HRFDCC) is an established interdisciplinary Center with a unique focus on Autosomal Recessive Polycystic Kidney Disease (ARPKD) and other single gene recessive HRFD disorders (NPHP, MKS, BBS, JBTS, OFD, etc.). The Center is multi-institutional with Cores located in three medical Universities in the Southeastern US. This multi-institutional format provides opportunities for integrating the unique research and clinical expertise that are housed in each of these institutions and to expand institutional support for Center’s activities. Further, the HRFDCC coordinates training and research opportunities with multiple NIH and University Centers including the UAB/UCSD O’Brien Center, UAB Nephrology Research and Training Center, and the Clinical and Translational Science Award (CTSA) programs at each institution. This allows the Center to expand activities far beyond that possible with only the P30 support. The overarching goals of the HRFDCC are: 1) to attract and support new scientific expertise and research into causes of HRFDs; 2); to facilitate the use of scientifically rigorous, state-of-the-art methodologies in a cost-effective manner to address HRFD pathogenesis; 3) to expand capabilities and specificity of diagnostic tools associated with HRFDs; and 4) to promote testing and development of efficacious treatments for HRFDs.

Funding

• NIH NIDDK